 
 
IGL/SE/2025-26/61 
 
18th November, 2025 
 
The Manager (Listing)   The Manager (Listing) 
BSE Limited  National Stock Exchange of India Limited 
1st Floor, New Trading Ring,   Exchange Plaza, C-1, Block G, 
Rotunda Building, P.J. Towers,   Bandra Kurla Complex, 
Dalal Street,                                                  Bandra (East), 
Mumbai – 400 001                          Mumbai- 400 051                                                             
  
Scrip Code: 500201    Symbol: INDIAGLYCO 
 
Dear Sirs, 
 
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure 
Requirements) Regulations, 2015 – Investor Presentation for Q2 & H1FY26 
Earnings Conference Call. 
  
Further to our letter bearing no. IGL/SE/2025-26/58 dated 7th November, 2025 and 
pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing 
Obligations and Disclosure Requirements) Regulations, 2015, an investor 
presentation is attached for the information of the investors. 
  
This same is also being hosted on the Company’s website at 
www.indiaglycols.com.  
 
 This is for your information and record. 
 
Thanking you,  
 
Yours truly,  
For India Glycols Limited 
 
 
 
Ankur Jain 
Head (Legal) & Company Secretary 
Encl: A/a 
 
 
 
 
Investor
Presentation
Q2 & H1 FY26 

Safe Harbor Statement
This presentation and the following discussion may contain “forward looking statements” by India 
Glycols Limited (“IGL” or the company) that are not historical in nature. These forward-looking 
statements, which may include statements relating to future results of operations, financial 
condition, business prospects, plans and objectives, are based on the current beliefs, assumptions, 
expectations, estimates, and projections of the management of IGL about the business, industry 
and markets in which IGL operates.
These statements are not guarantees of future performance, and are subject to known and 
unknown risks, uncertainties, and other factors, some of which are beyond IGL’s control and difficult 
to predict, that could cause actual results, performance or achievements to differ materially from 
those in the forward-looking statements. Such statements are not, and should not be construed, 
as a representation as to future performance or achievements of IGL.
In particular, such statements should not be regarded as a projection of future performance of IGL. 
It should be noted that the actual performance or achievements of IGL may vary significantly from 
such statements.
22
Table of Contents 
Q2 & H1 FY26 Financial Highlights
Q2 & H1 FY26 Segmental Highlights
Annual Financial Highlights
Annexures
Business Overview
Proposed Restructuring
02
03
05
06
04
01

Q2 & H1 FY26
Financial Highlights 
01

Q2FY26 Performance Overview
⦁ Overall, the company has reported a strong Gross and Net Revenue growth
⦁ EBITDA Margin has reported a healthy upside of 216 bps, with absolute EBITDA grew by 33% YoY 
Figures in ₹ Cr.
Consolidated Financials
2,144 
2,412 
Gross Revenue
Q2FY25 Q2FY26
50 65 
PAT & PAT Margin
Q2FY25 Q2FY26
961 1,092 
Net Revenue
Q2FY25 Q2FY26
+13%
120 
160 
EBITDA & EBITDA Margin
Q2FY25 Q2FY26
12.4% 14.6% 5.1% 5.9%
+14%
+33% +31%
55
H1FY26 Performance Overview
⦁ Strong sales in BF and PS segments have contributed to the growth in Gross and Net Revenue
⦁ EBITDA Margin was strongly supported by PS and BF segment, while BSPC also registered a modest margin expansion during the period
Figures in ₹ Cr.
Consolidated Financials
4,426 
4,916 
Gross Revenue
H1FY25 H2FY26
110 138 
PAT & PAT Margin
H1FY25 H1FY26
1,930 2,133 
Net Revenue
H1FY25 H1FY26
+11%
248 
311 
EBITDA & EBITDA Margin
H1FY25 H1FY26
12.8% 14.6% 5.7% 6.5%
+11%
+25% +26%
66
Highlights – Q2FY26
Net Revenue stood at ₹ 1,092 Cr in Q2FY26 vs. ₹ 961 Cr in Q2FY25, up by 13.6%
– BF increased by 62.9% to ₹ 423 Cr
– PS up by 24.5% YoY to ₹ 338 Cr
EBITDA increased by 33.0% at ₹ 160 Cr from ₹ 120 Cr, 
     - EBITDA Margin at 14.6% vs. 12.4% in Q2FY25, expanded by 216 bps 
Margins reported healthy improvement 
      - BF EBIT margins have increased from 5.1% to 6.9%
      - PS EBIT margins have improved from 20.5% to 21.4%
      - BSPC EBIT margins expanded from 8.1% to 10.9%
PAT stood ₹ 65 Cr in Q2FY26, up by 30.9%
       - PAT Margin stood at 5.9% as against 5.1% in Q2FY25
       - Share of profit in JV increased by 6.8% YoY to ₹ 12 Cr
Figures in ₹ Cr.
Consolidated Financials
Business Performance | Q2FY26 over Q2FY25
77
– BSPC stood at ₹ 288 Cr
– EB stood ₹ 43 Cr
Highlights – H1FY26
Net Revenue stood at ₹ 2,133 Cr in H1FY26 vs. ₹ 1,930 Cr in H1FY25, up by 10.5%
– BF increased by 54.5% to ₹ 770 Cr
– PS up by 23.4% YoY to ₹ 338 Cr
EBITDA increased by 25.1% at ₹ 311 Cr from ₹ 248 Cr, 
     - EBITDA Margin at 14.6% vs. 12.8% in H1FY25, expanded by 172 bps 
Margins registered a strong expansion 
      - BF margins increased from 6.4% to 6.8%
      - PS EBIT margins have improved from 19.0% to 21.3%
      - BSPC EBIT margins expanded from 9.0% to 10.9%
PAT stood ₹ 138 Cr in H1FY26, up by 25.6%
       - PAT Margin stood at 6.5% as against 5.7% in H1FY25
       - Share of profit in JV increased by 40.1% YoY to ₹ 30 Cr from ₹ 22 Cr
Figures in ₹ Cr.
Consolidated Financials
Business Performance | H1FY26 over H1FY25
88
– BSPC stood at ₹ 588 Cr
– EB stood ₹ 94 Cr
Particulars Q2FY26 Q2FY25 Y-o-Y (%) H1FY26 H1FY25 Y-o-Y (%)
Gross Revenue from Operations 2,412 2,144 12.5% 4,916 4,426 11.1%
Revenue from Operations (Net of excise) 1,092 961 13.6% 2,133 1,930 10.5%
Other Income 2 4 4 7
Total Income 1,094 966 13.3% 2,136 1,937 10.3%
EBITDA 160 120 33.0% 311 248 25.1%
EBITDA Margin 14.6% 12.4% 216 bps 14.6% 12.8% 172 bps
Depreciation 38 28 73 55
EBIT 121 93 238 193
Finance Cost 49 40 94 76
Exceptional Items - - - -
Share of net profit / (loss) of joint venture 12 11 30 22
PBT 84 63 31.8% 174 139 25.2%
Tax Expenses 19 14 36 29
Profit / (Loss) for the Period 65 50 30.9% 138 110 25.6%
PAT Margin 5.9% 5.1% 80 bps 6.5% 5.7% 79 bps
EPS (₹) 10.5 16.1 22.3 17.8
Financial Summary - Consolidated
Figures in ₹ Cr.
99
Particulars Q2FY26 Q2FY25 Y-o-Y (%) H1FY26 H1FY25 Y-o-Y (%)
Gross Revenue from Operations 2,411 2,144 12.5% 4,914 4,426 11.0%
Revenue from Operations (Net of Excise) 1,091 961 13.5% 2,131 1,930 10.4%
Other Income 2 4 4 7
Total Income 1,093 965 13.2% 2,134 1,937 10.2%
EBITDA 160 121 32.8% 310 246 25.8%
EBITDA Margin 14.7% 12.5% 216 bps 14.5% 12.7% 179 bps
Depreciation 38 28 73 55
EBIT 122 93 237 191
Finance Cost 49 40 94 76
Exceptional Items - - - -
PBT 72 53 36.3% 143 115 23.8%
Tax Expenses 19 14 36 29
Profit / (Loss) for the Period 54 39 36.7% 107 86 23.9%
PAT Margin 4.9% 4.1% 85 bps 5.0% 4.5% 55 bps
EPS (₹) 8.7 6.4 17.2 13.9
Financial Summary - Standalone
Figures in ₹ Cr.
1010
JV business reported a softer quarter both in terms of sales and EBITDA due to a general slow down and pressure both on domestic and 
export markets. In H1, JV business reported strong PAT growth of 36% on the back of improved product mix
Post the execution of Stock Split/ Sub-division of the equity shares of the company on 12th August 2025, the equity shares has been increased 
from 3,09,61,500 Equity shares to 6,19,23,000 equity shares
The Board of Directors of the parent company at their meeting held on 16th October ,2025 had considered and approved the Raising funds 
through Issuance of up to 51,03,765 Equity Shares of Face Value of Rs. 5/- each, at a price of Rs. 915/- per Equity Share, (including a premium of 
Rs. 910/- per equity share), determined in accordance with the provisions of Chapter V of SEBI (Issue of capital and Disclosure Requirements) 
Regulations, 2018 ("SEBI ICDR Regulations"), for cash, for an aggregate amount of up to Rs. 466.99 Cr on preferential basis and the same has 
been approved by the shareholders of the company at their Extraordinary General Meeting held on November 12, 2025. Further, the company 
has filed an application with Stock Exchanges for in-principle approval of the proposed Issue, and the same Is under process with the 
exchanges
Highlights – Q2 & H1 FY26
Consolidated Financials
Other Highlights
1111
Q2 & H1 FY26 
Segmental 
Highlights
02

369 288
 -
 100
 200
 300
 400
 500
 600
 700
Q2FY25 Q2FY26
Bio-Based Specialties and 
Performance Chemicals (BSPC)
271 338
 -
 50
 100
 150
 200
 250
 300
 350
 400
 450
 500
Q2FY25 Q2FY26
Potable Spirits (PS)
61 43
 -
 50
 100
 150
 200
 250
 300
Q2FY25 Q2FY26
Ennature Biopharma (EB)
Figures in ₹ Cr.
Segmental Highlights – Q2FY26
8.1% 10.1% 20.5% 21.4%
9.0% 2.3%
Net Revenue and EBIT Margin (%)
Consolidated Financials
260
423
 -
 100
 200
 300
 400
 500
 600
 700
 800
Q2FY25 Q2FY26
Bio-Fuel (BF)
5.1% 6.9%
1313
763 588
 -
 100
 200
 300
 400
 500
 600
 700
 800
 900
 1,000
H1FY25 H1FY26
Bio-Based Specialties and 
Performance Chemicals (BSPC)
551 680
 -
 100
 200
 300
 400
 500
 600
 700
 800
 900
 1,000
H1FY25 H1FY26
Potable Spirits (PS)
118 94
 -
 50
 100
 150
 200
 250
 300
H1FY25 H1FY26
Ennature Biopharma (EB)
Figures in ₹ Cr.
Segmental Highlights – H1FY26
9.0% 10.9% 19.0% 21.3%
10.1% 2.3%
Net Revenue and EBIT Margin (%)
Consolidated Financials
499
770
 -
 200
 400
 600
 800
 1,000
 1,200
 1,400
H1FY25 H1FY26
Bio-Fuel (BF)
6.4% 6.8%
1414
39%
27%
28%
6%
Q2FY25Q2FY26
29%
13%
53%
5%
Q2FY26 Q2FY25
Revenue Mix EBIT Mix
26%
39%
31%
4%
23%
22%54%
1%
Segmental Revenue and EBIT Mix – Consolidated – Q2FY26 
Consolidated Financials
BSPC PS EBBF
1515
39%
26%
29%
6%
H1FY25H1FY26
32%
15%
48%
5%
H1FY26 H1FY25
Revenue Mix EBIT Mix
28%
36%
32%
4% 24%
20%55%
1%
Segmental Revenue and EBIT Mix – Consolidated – H1FY26 
Consolidated Financials
BSPC PS EBBF
1616
Particulars Q2FY26 Q2FY25 % YoY H1FY26 H1FY25 % YoY
Portable Spirits (PS)
Net Revenue 338 271 24.5% 680 551 23.4%
EBIT 72 56 30.0% 145 105 38.1%
% margin 21.4% 20.5% 21.3% 19.0%
PS delivered ₹ 338 Cr revenue, up 24.5% YoY, EBIT of ₹ 72 Cr, up 30.0% YoY; margin improved to 21.4% from 20.5% in Q2FY25
H1FY26 revenue at 680 Cr, up 23.4% YoY with EBIT of 145 Cr, up 38.1% YoY. Margin expanded to 21.3% in H1FY26 from 19.0% in H1FY25
Amrut Partnership picking up traction in UP, UK, Delhi with increasing focus on premium brands. Market Entry into CSD planned in this year
Continued solid performance in CL, Market share gained in UK
Expanding Market in South (Kerala): Secured approval and started supply of  in-house brands i.e. Zumba Lemoni, Soulmate Blu and Amazing 
Vodka & further planning of launching a Brandy Brand
Strengthening footprint in the Paramilitary business, reinforcing commitment to institutional channels
Segment Performance - PS 
Consolidated Financials
Figures in ₹ Cr.
1717
Particulars Q2FY26 Q2FY25 % YoY H1FY26 H1FY25 % YoY
Bio-based Specialities and Performance Chemicals (BSPC)
Net Revenue 288 369 (21.9%) 588 763 (22.8%)
EBIT 31 30 5.0% 64 69 (6.8%)
% margin 10.9% 8.1% 10.9% 9.0%
BSPC achieved ₹ 288 Cr revenue with EBIT of ₹ 31 Cr; Margin expanded to 10.9% from 8.1% in Q2FY25
H1FY26 revenue at ₹ 588 Cr, with EBIT at ₹ 64 Cr; Margin expanded to 10.9% in H1FY26 from 9.0% in H1FY25
Continued strong pipeline with strong margin growth expected to continue
Incremental capacity expansions being executed. 
Segment Performance – BSPC
Consolidated Financials
Figures in ₹ Cr.
1818
Particulars Q2FY26 Q2FY25 % YoY H1FY26 H1FY25 % YoY
Bio Fuel
Net Revenue 423 260 62.9% 770 499 54.5%
EBIT 29 13 121.4% 52 32 62.9%
% margin 6.9% 5.1% 6.8% 6.4%
Bio Fuel delivered ₹ 423 Cr revenue (+62.9% YoY) with EBIT of ₹ 29 Cr (+121.4% YoY); margin expanded to 6.9% from 5.1% in Q2F Y25
In H1FY26, revenue increased by 54.5% YoY to ₹ 770 Cr, with EBIT grew by 62.9% YoY to ₹ 52 Cr
Strong biofuel growth supported by expanded capacity to meet government blending program requirements
Overall, India’s blending program on track to achieve 20% blending target
Overall blending average achieved for ESY 24-25 is 19.75% (between Nov-24 to Sep-25), Expected ESY blending ~19.70%
Segment Performance – Bio-Fuel
Consolidated Financials
Figures in ₹ Cr.
1919
Particulars Q2FY26 Q2FY25 % YoY H1FY26 H1FY25 % YoY
Ennature  Biopharma (EB)
Net Revenue 43 61 (28.7%) 94 118 (20.2%)
EBIT 1 6 (82.2%) 2 12 (81.8%)
% margin 2.3% 9.0% 2.3% 10.1%
EB revenue at ₹ 43 Cr in Q2FY26 and ₹ 94 Cr in H1FY26
Overall challenging operating environment seen in EB
Volatility in Thiocolchicoside market continues due to disruptions in Gloriosa seed supply
Nicotine sales under pressure due to increased competition and price pressure 
Continued focus on strengthening Branded Nutraceuticals portfolio through various strategic initiatives
Segment Performance - EB 
Consolidated Financials
Figures in ₹ Cr.
2020
Proposed 
Restructuring
03

Revised Proposed Scheme and Structure
Kashipur Holdings 
Limited (KHL)
Promoter Group
95.78%
India Glycols Limited (IGL)
IGL Spirits Limited (ISL) Ennature Bio Pharma 
Limited (EBL)
Demerger of 
business 
into 2 separate 
entities
KHL currently holds
50.35% in IGL
Management of IGL to enter 
into a composite scheme of 
arrangement for the 
following:
 Demerger of Potable Spirits & Bio-
fuel and Bio-pharma Businesses – 
respective businesses to be 
transferred by way of demerger to 
the respective companies – ISL and 
EBL respectively
 Discharge of demerger 
consideration – Subsidiaries to 
issue shares to the shareholders of 
the IGL
 The shares issued by EBL and ISL 
shall be listed on BSE Limited and 
the National Stock Exchange of 
India Limited subject to necessary 
approvals
EBL shall issue 1 (One) Equity Share 
having face value INR 5 (Indian Rupees 
Five) each, to the shareholders of 
IGL holding 3 (Three) Equity Shares of INR 
5 (Indian Rupees Five) each
ISL shall issue 1 (One) Equity Share 
having face value INR 5 (Indian 
Rupees Five) each, to the 
shareholders of IGL holding 1 (One) 
Equity Share of INR 5 (Indian Rupees 
Five) each
Post restructuring Promoters holding will be 61.01% in each of the three companies i.e. IGL, ISL, and EBL
Note: The Company has withdrawn the earlier proposed composite scheme of amalgamation of Kashipur Holding Limited (KHL) into India Glycols Limited (IGL).
However, such withdrawal and simultaneous approval of Modified Scheme would not have any impact on the interest of the stakeholders including public shareholders as they will continue to own the same 
percentage of shares in IGL and Resulting Companies 2222
Proposed Business Structure (FY 2024-25)
Figures in ₹ Cr.
Standalone Financials * Formerly Ennature Bio Pharma Private  Limited 
India Glycols Limited
Chemicals Business Glycols, Bio 
Glycols, New Specialty Products
Industrial Gases Business
Ennature Bio Pharma Limited *
Bio Pharma Business
Bio Polymers Business
IGL Spirits Limited
Spirits Business 
IMFL, Country Liquor
Bio-Fuel Business
₹ 1,302 Cr
₹ 1,302 Cr
34.6%
₹ 7,477 Cr
₹ 2,207 Cr
58.6%
₹ 258 Cr
₹ 258 Cr
3.2%
Bio-based Specialties and 
Performance Chemicals
Glycols, Glycol Ethers New 
Specialties, Bio Polymers, ENA, 
Gases
Bio-Fuel
Bio-Fuel
Potable Spirits
IMFL
Country Liquor
Ennature Biopharma
Bio Pharma
₹ 1,341 Cr
₹ 1,341 Cr
35.6%
₹ 1,044 Cr
₹ 1,044 Cr
27.7%
₹ 6,434 Cr
₹ 1,163 Cr
30.9%
₹ 219 Cr
₹ 219 Cr
5.8%
Post Restructuring
Existing Structure
Entire IGL Business will be demerged into 3 separate companies
23
Gross Sales
Net Sales
% Share
Gross Sales
Net Sales
% Share
23
Benefits of the Proposed Scheme
Each business will have a 
clear focus, leading to 
improved management 
and resource allocation 
for growth
Will create a potential to 
unlock value for 
stakeholders by drawing 
focused investors
Each business will manage its 
capital, investments, and 
resources based on its specific 
needs, ensuring more efficient 
capital use
Separating the 
businesses will reduce the 
risk of one business 
affecting the others
Each business will adhere to 
regulations that are specific 
to its industry
The demerger will enable 
independent growth for 
each business
The proposed restructuring is in the interest of the shareholders, creditors, employees, and other stakeholders in each of the companies
2424
Business
Overview
04

Exporting to 40+ 
countries 
Potable Spirits 
(PS)
Ennature Biopharma 
(EB) 
IGL is one of the leaders in BSPC 
segment and offers a myriad range of 
products to different sectors to satisfy 
the evolving needs of customers and 
end-use applications across 
numerous categories
Leading manufacturer of Country 
Liquor and Indian Made Foreign Liquor 
(IMFL), known for producing high-
quality alcohol products, using state-
of-the-art technology and advanced 
production processes
The natural ingredients division of IGL, 
built on the foundation of Nature, 
Technology and Innovation. The EB 
segment provides high-quality, 
differentiated solutions for the 
pharmaceutical, nutraceutical, and 
food & beverage industries
Company at a Glance
IGL started selling Bio-Fuels to OMCs 
in India through its grain-based 
distillery capacities. 
Bio FuelBio-based Specialties & 
Performance Chemicals (BSPC) 
35%
28%
31%
6%BSPC
Bio-Fuel
PS
EB
FY25 Revenue share
₹ 3,768 Cr
FY25 Net Revenue
₹ 525 Cr
FY25 EBITDA
₹ 231 Cr
FY25 PAT
100+ 
Green products
3 Integrated manufacturing facilities spread over area of ~360 acres
Business Overview
India Glycols Limited (IGL), founded in 1983, is one of the leading manufacturer of Bio-based Specialties & Performance Chemicals (BSPC), Bio-
Fuel, Potable Spirits (PS) and Ennature Biopharma (EB). It is the first company in the world to produce Ethylene Oxide (EO) / Mono Ethylene 
Glycol (MEG) from renewable Agro route based on molasses since 1989. IGL has a diversified portfolio with exposure in Bio-based Specialties, 
Bio-Polymers, Plant based APIs & Nutraceuticals, Potable Spirits, Gases, Biofuels, and others. IGL has a global presence and partners in various 
countries, with a rich legacy of over three decades in innovation and sustainability. 
26
Key Strengths
27
3+ decades of presence 
Diversified business model and 
applications
India’s leading Green Chemical 
Company 
Integrated Manufacturing facilities – 
3 facilities located in Kashipur, 
Gorakhpur and Dehradun 
3x3 strategy for Cost Effectiveness
R&D: Creating value with focus 
on Green Chemistry & Technical 
collaborations 
Financial Performance  - Strong 
Credit Profile (A- Stable from Care 
Ratings) with low gearing ratio
Strong Management Team
27
IGL Journey of more than 3 decades
1983-2000 2001 - 2007 2008-2014 2023-20252015-2022
1983: Incorporation as UP 
Glycols Ltd
1986: Renamed to India 
Glycols Ltd
1989: Commercial production 
of MEG plant
1994: Commissioning of EO 
purification and first 
Ethoxylation plant 
1995: Expansion of MEG plant
1997: Commissioning of 
formulation sulphation plant 
1998: Further Expansion of 
MEG Facility and formulation 
sulphation plant
2001: Starting of glycol 
ether plant and gaur gum 
plant
2002: Commissioning of 
bottling plant and 
expansion of MEG facility
2003: Addition of GE 
acetate facility, 
Commissioning of Extra 
Neutral Alcohol (ENA)
2005: Expansion of MEG 
plant
2006: Commissioning of 
Gorakhpur Distillery unit 
2008: Expansion of MEG 
plant and commissioning 
of CO2 plant
2009: Commissioning of 
Ennature Biopharma unit in 
Dehradun 
2010: Biomass based 
cogeneration at Gorakhpur 
registered under CDM 
project by UNFCCC
2013: Incorporation of US 
subsidiary
2015: Bio-polymers 
expansion
2019: Thiocolchicoside 
Nicotine expansion
2020: Commissioning of 
sanitizer manufacturing
2021: JV with Clariant and 
manufacturing of IMFL 
brands 
2022: New grain-based 
Ethanol plant at Gorakhpur 
and Kashipur 
2023: Sale of entire stake in 
Shakumbari Sugar and Allied 
Industries Limited (SSAIL) and 
Kashipur Infrastructure & 
Freight Terminal Pvt. Ltd., 
both non-core assets; 
Commissioning of NSU 
Phase-I
2025: Incorporation of wholly 
owned subsidiary IGL Spirits 
Limited
2828
Diversified business model and multi-functional 
application
Applications
Bio Glycols: Bio Mono Ethylene Glycol, Bio Di Ethylene Glycol, etc.
Bio Glycols ethers: Ethylene Glycol Monoethyl Ether, Acetate, etc.; Only 
manufacturer in India to use a continuous process with world-renowned 
‘Sulzer Chemtech’ technology. Integration of its captive feedstock of 
ethylene oxide and ethyl alcohol
Bio-polymers: Hydroxypropyl Guar, Bio-Polymer products, etc. 
Specialities: Plasticizers, Oil fields chemicals, Bio-amines, etc. 
Speciality gases: Liquid oxygen, CO2, Liquid argon and nitrogen, etc.
Business segments
Bio-based Specialities and Performance Chemicals (BSPC)
License for operations and sale of Country Liquor in the States of Uttar 
Pradesh and Uttarakhand. Also operates and sells IMFL from its own unit 
and few tie-up units, and Molasses & Grain based ENA
Offers Whisky, Vodka, Rum, Economy Spirits under brands - Amazing 
Vodka, Single Reserve Whiskey, Amazing Green Apple, Amazing Orange, 
Amazing Plain, Soulmate Gin, V2O Orange Vodka aand Zumba Lemon
Company brands are available in the states of Uttarakhand, Uttar 
Pradesh, Delhi and Himachal Pradesh
Registered supplier to Indian Defense forces through CSD, continuing 
Brand-premiumization plan, will endeavor to introduce premium brands
Potable Spirits (PS)
Nutraceuticals, Phytochemicals, Health supplement ingredients, Liquid 
Nicotine & various salts
Global leader in Thiocolchicoside, a highly potent muscle relaxant API
Ennature maintains germ plasm for herbs like artemisia, stevia, rosemary, 
marigold and sage among others
Launched Maxicuma (a curcumin formulation) in nanotized form which is more 
bioavailable than curcumin itself
These are transferred to farmers who have contract cultivation agreements 
with IGL for buy-back
Ennature Biopharma (EB) Bio-Fuel
Special Grade of Ethanol for petrol blending
Automotive
Beverage and food 
Packaging 
Textile
Oil & Gas
Paint and Coating
Pharma & Healthcare
Electronic Chemical 
industries
Agrochemicals 
Personal Care
Detergents
Mining
Perfumery
Glass 
Metal / Steel, 
Pulp & paper
Wastewater 
treatment
Lighting
Construction
Revenue Share (FY25): 36%  |   EBIT Share (FY25): 27% Revenue Share (FY25): 31%  |  EBIT Share (FY25): 56%
Revenue Share (FY25): 6%  |  EBIT Share (FY25): 5% Revenue Share (FY25): 28%   |  EBIT Share (FY25): 12%
29
Green is in IGL’s DNA and is the core of our business: Inspired by nature and Green chemistry, we create compounds based 
on decades of expertise, innovative engineering and sustainable technologies, while ensuring our environment remains 
untouched.
Only manufacturer in the world to produce 
bio-ethylene glycols (MEG, DEG and TEG) 
using bio-ethanol
World’s only company with all types of standard 
and high-quality derived biopolymers products, 
also known as hydrocolloids
India’s largest and only 
manufacturer for bio-glycol ethers 
Company’s Country Liquor is made 
from Grain ENA and Molasses
Ennature R&D focussed on diverse requirements 
for plant-based APIs and Nutraceuticals – 
patents for Lutein ester extraction
World’s 1st and largest manufacturer of Bio-based 
ethylene oxide and derivatives using Innovative 
Green Technologies from bio-based/renewable 
feedstocks i.e., Molasses and Grain
Leading manufacturer of Nutraceuticals, APIs, etc., 
adopting green technology of Highly Selective 
Supercritical Fluid Extraction (SCFE-CO2)
India’s leading Green Chemical Company 
3030
Integrated Manufacturing facilities 
Kashipur
300-acre state 
of art integrated 
manufacturing 
complex
 Fermentation – Molasses and Grain Based
 Ethanol Distillation, Extra Purification
 Biofuels
 Grain based Ethanol
 Ethylene Oxide, High purity EO
 Glycols ( MEG, DEG, TEG and derivatives)
 Green solvents based on Glycol Ethers and 
Glycol Ether Acetates
 Specialties and Performance Chemicals
 Branded CL Bottling
 IMFL
 Industrial Gases – Oxygen, Nitrogen, Argon, CO2
 State-of-the-art manufacturing facilities 
approved and certified by international agencies
 Reliable supply; integration of its captive 
feedstock of ethylene oxide and ethyl alcohol
 Manufacturing of Biopolymers other hydrocolloids 
products with specialty PO derivatized guar
Gorakhpur
56-acre state of 
art distillation & 
bottling complex
 Grain based Ethanol
 Fermentation
 Ethanol Distillation
 Ethanol Extra Purification
 Ethanol Bio Fuel Grade
 Branded CL Bottling
 IMFL bottling Tetra
 IMFL Glass bottling
Dehradun
1,60,000 sqft state 
of art facility
 High Purity Extraction
 SCFE (Super Critical CO2)
 Solvent Extraction
 Aqueous Extraction
 Bio Fermentation
Capabilities
3131
Leveraging synergies to create value–integrated manufacturing 
for bio-based products
RAW MATERIAL PROCESS FINISHED GOODS
Green 
Performance
Chemicals
Bio-EODs
Business transferred 
to JV with Clariant
Molasses Distillery Bio-Ethylene
Outsourced
Bio-Ethanol
Bio-Ethanol
Sugar Plant 
Sugarcane
Grain
CS
Glycols
ENA Potable 
Spirit Brands
Power 
Alcohol
EO-CO2 mix
Ind Gr. CO2
O2, N2, Ar
Bio- EO
O2 ASU
Bio-Glycols
Industrial 
Gas Division
CS EthyleneEthanol from 
emissions
CS Ethylene 
Oxide
Carbon 
Smart EODs
CarbonSmart
Performance 
Chemicals Future Products 
under BSPC
Bio-based Specialities
And Performance
Chemicals (BSPC) 
Products
Portable Spirits (PS) Products
CS Ethylene 
Oxide
CS
Glycols
3232
Domestically 
bought Ethanol
In-house 
Ethanol
Imported 
Ethanol
Bio-fuels
Bio-based 
Chemicals
Potable 
Spirits
Mitigating costs with 3 possible
sources of raw material
3 possible 
outputs
 Ethanol plants capacities (including grain-based) of 600 KLPD and 500 KLPD at Kashipur and Gorakhpur sites respectively, running up to optimum level have enabled 
the company to operate on this 3X3 model and helped in mitigating the impact of increase in ethanol cost. 
3 x 3 Strategy for Cost Effectiveness 
3333
IGL pioneers’ sustainable trends with innovative, technology-driven solutions that reduce carbon footprints, 
leveraging digital technologies to reach net zero emissions and lead the way in green innovation. The state-of-the-
art R&D centre has been approved by the Department of Scientific & Industrial Research (DSIR) since 1993.
 Next-generation research and technological advancements add value to sustainable products made from 
renewable resources 
 Creating limitless possibilities through green engineering by using agricultural, horticultural, and forest waste, as 
well as released carbon
Creating Unmatchable USPs
Green Products: Derived from renewable 
and C-smart resources
Consistent quality: State-of-the-art, DCS-
controlled manufacturing
Minimum carbon footprint: Waste to 
chemicals
High quality products: Minimum 
impurities
Customised product design: 
Collaborative R&D and innovation
Environment and eco-friendly: 
Biodegradable
Technical collaborations & Tie-ups
US-based Scientific Design Inc. to 
produce high-quality bio-glycols
Global tech partnership with Wittemann, 
Hitachi, Air Liquide and Praxair
Tie-up with Bacardi for bottling of their 
products at the Kashipur bottling unit
LanzaTech for manufacturing of specialty 
chemicals based on C-smart alcohol 
Using world-renowned ‘Sulzer Chemtech’ 
technology for Glycol ethers and 
acetates - Only manufacturer in India
JV with Clariant, leader in bio-based 
ethoxylates and derivatives
New range of products in pipeline:
i) Products derived from C-smart or 
Purple alcohol
ii) Bio Based specialties 
iii) iGreen solvents including a range of 
bio-esters, Specialty Bio-amines etc. 
iv) Specialty derivatives of Poly-
galactomannans
v) APIs and Nutraceuticals
Focusing on following major 
industry sectors: 
i) Oil & Gas Industry including refineries, 
ii) Automobiles
iii) Metal working Industry 
iv) Industrial and institutional cleaning
v) Rheology modifiers for Petroleum 
Industry
vi) Food Industry 
vii) Health care
R&D: Creating value through focus on Green Chemistry with 
Technical collaborations
34
Growth Drivers
State-of-the-art of 
technology adopted to 
produce specialty chemicals 
of global quality standards
Increasing consumer 
awareness and demand for 
sustainable products
Companies taking steps to 
significantly decrease carbon 
footprint in line with USDG 
targets
Growing demand for natural 
and safer products in 
pharma, nutraceuticals, 
cosmeceuticals, food 
ingredients
IGL is ideally placed to seize 
the opportunity arising out 
the increasing demand for 
ingredients derived from 
renewable resources and 
CarbonSmart feed stocks; 
alternatives to ingredients 
derived from fossil fuels
High prospects of growth of 
industry sectors being 
serviced by IGL – Personal 
Care, Automotive, Packaging, 
Beverages, Oil & Gas, Home 
Care, Pharma, Nutraceuticals 
etc, Textiles – most expected 
to grow at near double digit 
or more
Regular R&D and innovation 
support for products as well 
as their applications
IGL has established itself as a 
reliable partner for its 
customers, with high degree 
of sustainability
Collaborative R&D tie-ups 
with leading global players  
for forward and backward 
integration of products
Success stories of IGL 
from the experiences so 
far will serve as the key 
driver of growth
3535
Annual Financial 
Overview
04

3-year Financial Trajectory - Consolidated
6,642 
7,922 9,039 
FY23 FY24 FY25
Gross Revenue
319 
428 525 
FY23 FY24 FY25
EBITDA & EBITDA Margin (%)
141 173 
231 
FY23 FY24 FY25
Adj. PAT* & Adj. PAT Margin (%)
11.9% 12.9% 13.9% 5.3% 5.2% 6.1%
* PAT adjusted for Exceptional Income of ₹ 28.13 Cr. in FY23 on account of Sale of Kashipur Infrastructure and Freight Terminal Pvt. Ltd. 
Figures in ₹ Cr.
2,651 
3,294 
3,768 
FY23 FY24 FY25
Net Revenue
3737
3-year Key Ratios - Consolidated
0.58 0.64 
0.80 
FY23 FY24 FY25
Debt-to-Equity Ratio (x)
59 
43 
64 
FY23 FY24 FY25
Cash Conversion Cycle* (Days)
2.26
2.71 2.50
FY23 FY24 FY25
Interest Coverage Ratio (x)
* Cash Conversion Cyle = Debtor Days + Inventory Days – Creditor Days
7.7%
10.5% 11.6%
FY23 FY24 FY25
Return on Capital Employed (%)
3838
Particulars (In ₹ Cr) FY23 FY24 FY25 FY23-25 CAGR
Gross Revenue from operations 6,642 7,922 9,039 16.7%
Revenue from operations (Net of excise) 2,651 3,294 3,768 19.2%
Other Income 24 26 15
Total Income 2,675 3,320 3,783 18.9%
EBITDA 319 428 525 28.3%
EBITDA Margin 11.9% 12.9% 13.9%
Depreciation 94 101 115
EBIT 225 327 410 34.9%
Finance Cost 100 121 164
Exceptional Items 28 - -
Share of net profit / (loss) of joint venture 11 17 46
PBT 165 223 292 33.1%
Tax Expenses 24 50 61
Profit / (Loss) after tax from continuing operations 141 173 231
Profit / (Loss) after tax from discontinued operations - - -
Profit / (Loss) for the period 141 173 231 28.0%
PAT Margin for continued operations 5.3% 5.2% 6.1%
Adjusted Profit / (Loss) for the period * 113 173 231 28.0%
Adjusted PAT Margin for continued operations * 4.2% 5.2% 6.1%
EPS for continued operations 45.6 55.9 74.6
Financial Summary - Consolidated
* PAT adjusted for Exceptional Income of ₹ 28.13 Cr. In FY23 on account of Sale of Kashipur Infrastructure and Freight Terminal Pvt. Ltd. 
Figures in ₹ Cr.
3939
Financial Summary - Consolidated
Balance Sheet Cash Flow Statement
Particulars (₹ Cr.) (as at end of) FY23 FY24 FY25
Fixed Assets 2,690 3,171 3,736
CWIP 125 84 98
Investment 318 335 381
Other Financial Assets 44 43 45
Other Non-Current Assets 35 40 100
Trade Receivables 430 384 365
Cash and Bank Balance 113 138 77
Inventory 754 1,106 1,171
Other Current Assets 349 316 203
Total Assets 4,858 5,617 6,176
Shareholders Fund 1,901 2,051 2,256
Long Term Borrowings 551 725 1,040
Non-Current Liabilities 541 466 559
Trade Payables 752 1,099 979
Short Term Borrowings 547 596 764
Other Current Liabilities 566 679 578
Total Liabilities 4,858 5,617 6,176
Particulars (₹ Mn) FY23 FY24 FY25
Cash and Cash Equivalents (Opening Balance) 7 2 27
Cash Flow from Operating Activities (A) 326 439 362
Cash Flow from Investing Activities (B) (330) (503) (736)
Cash Flow from Financing Activities (C) (1) 90 354
Net Increase in Cash and Cash Equivalents 
(A+B+C) (5) 25 (20)
Cash and Cash Equivalents (Closing Balance) 2 27 7
Figures in ₹ Cr.
4040
Annexures05

Promoters, 
61.01%
FII, 2.62%
Domestic 
Institutions, 
1.33%
Bodies 
Corporates, 
2.96%
Public & 
Others, 32.08%
Shareholder Information as on 30th September 2025
BSE Ticker 500201
NSE Symbol INDIAGLYCO
Market Cap (in ₹ Cr.) 2,657.12
% Free- float 38.99%
Free Float Market Cap (in ₹ Cr.) 1,036.01
Shares Outstanding (Cr.) 3.10
3M ADTV (Shares) 1,90,600
3M ADTV (in ₹ Cr.) 22.84
Industry Chemicals
as on 
30th September 2025
Shareholding Pattern
Shareholder’s Information
4242
Sustainability, ESG
 Adherence to high safety and operational 
standards for handling hazardous materials.
 Employee and worker training for skill 
development.
 Implementation of preventive measures to 
enhance cyber security.
 Provision of health, accident insurances, and 
maternity benefits for employee well-being.
 Regular meetings of the Environment Health 
& Safety Committee.
 Documentation of Standard Operating 
Procedures.
Social
 Stakeholder engagement approach 
implementation.
 Compliance with relevant laws and 
regulations.
 Effective risk management framework 
implementation.
 Ensuring transparency in financial reporting
 Maintaining a diverse, compliant and 
independent Board of Directors
Governance
 Utilization of briquettes made from plant 
waste.
 Installation of Zero Liquid Discharge 
(ZLD) systems at distilleries.
 Recycling of hazardous waste through 
MoEF & CC approved recyclers.
 Constant search for alternative green 
feedstocks.
 Strengthening the R&D team to develop 
sustainable products with bio-based 
and sustainable raw materials.
 Reduction in volatile organic chemicals 
from the MEG plant.
 Decrease in microbial load in water 
used.
Environment
4343
Thank You
India Glycols Limited
CIN: 
L24111UR1983PLC009097 
Head office
2B, Sector-126, Noida
Gautam Budh Nagar
Uttar Pradesh 201304
Tel: +91-120-6860000, 3090100, 3090200
Fax: +91-120-3090111
Email: investor.relations@indiaglycols.com
Ankur Jain
Company Secretary &
Compliance Office
Ernst & Young LLP
Rohit Anand
rohit.anand4@in.ey.com
Riddhant Kapur
Riddhant.kapur@in.ey.com

